"Dideoxynucleosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription.
| Descriptor ID |
D015224
|
| MeSH Number(s) |
D13.570.230.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dideoxynucleosides".
Below are MeSH descriptors whose meaning is more specific than "Dideoxynucleosides".
This graph shows the total number of publications written about "Dideoxynucleosides" by people in this website by year, and whether "Dideoxynucleosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dideoxynucleosides" by people in Profiles.
-
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023 08; 10(8):e506-e517.
-
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. Antivir Ther. 2023 02; 28(2):13596535231168480.
-
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV. 2022 01; 9(1):e24-e31.
-
Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
-
Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e70-e77.
-
Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Trop Med Int Health. 2018 06; 23(6):650-660.
-
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One. 2017; 12(7):e0181357.
-
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa. PLoS One. 2017; 12(7):e0180645.
-
Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis. Pediatr Infect Dis J. 2014 Jun; 33(6):617-22.
-
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.